FDAnews Drug Daily Bulletin

MORPHOSYS ENTERS ANTIBODY PACT WITH U.S. MERCK

Dec. 16, 2005
A A

MorphoSys has signed a licence agreement with U.S. drugmaker Merck & Co. Inc. (MRK.N: Quote, Profile, Research) for the use of MorphoSys's human therapeutic antibody technology, the German biotech firm said on Wednesday. As part of the five-year agreement for the use of MorphoSys's HuCAL GOLD and AutoCAL technologies, MorphoSys will receive an up-front payment, annual user fees and research and development funding, MorphoSys said in a statement.

Reuters (http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh48278_2005-12-14_07-24-37_l14373427_newsml)